Everest Medicines Acquires Exclusive Rights to Novel Biologic for Eye Disorders
Everest Medicines has acquired an exclusive license to develop and commercialize VIS-101, a novel bifunctional biologic for serious eye disorders, in Greater China and other Asian countries.
- Countries included in the license: Greater China, Singapore, South Korea, and certain Southeast Asian countries
- Partnership with Visara, Inc., a subsidiary of NovaBridge Biosciences (Nasdaq: NBP)
- Upfront payment: US$7 million (approximately RMB49.7 million)
- Reimbursement for prior expenses: up to RMB24.0 million
- Potential future payments: up to US$89 million
Collaboration marks Everest's strategic expansion into ophthalmology, a high-potential therapeutic area.
Author's summary: Everest Medicines expands into ophthalmology with exclusive license to VIS-101.
More News
- Billie Eilish Calls on Billionaires to Do More for People in Need
- Norway’s proposal to double krill harvests raises tension at Antarctic conservation summit
- Opinion: Data centers are a win for Missouri - The Missouri Times
- Apple promises blockbuster Christmas iPhone sales, after quarterly miss
- San Diego County’s Most Expensive Home Is This $50 Million Beachfront Estate in Del Mar
- Park | Sliwa Should Not and Will Not Drop Out